Abstract: |
The endothelin-1 antagonist, atrasentan (ABT-627) was used to modify perfusion in the human tumor xenograft model, HT29, growing in nude mice. Atrasentan produced a significant increase in perfusion, as measured in vivo by Gd-DTPA DCE-MRI. Changes in tumor hypoxia were assessed by comparing the binding of two hypoxia tracers, pimonidazole and EF5 given before and after Atrasentan administration. In vehicle-treated controls, the distribution of EF5 and pimonidazole was very similar. However, Atrasentan treatment was associated with decreased uptake of the second hypoxia tracer (EF5), relative to the first (pimonidazole). Although Atrasentan had no independent effect on the growth of HT29 tumors, Atrasentan combined with 20 Gy radiation led to a modest but significant increase in tumor growth delay compared to radiation alone. © 2009 Landes Bioscience. |
Keywords: |
immunohistochemistry; controlled study; treatment outcome; human cell; nonhuman; combined modality therapy; nuclear magnetic resonance imaging; magnetic resonance imaging; adenocarcinoma; mouse; animals; mice; radiotherapy; animal experiment; animal model; colonic neoplasms; antineoplastic activity; tumor xenograft; drug effect; xenograft model antitumor assays; radiation injury; colorectal carcinoma; hypoxia; cancer inhibition; mice, nude; quantitative analysis; pimonidazole; gadolinium pentetate; gadolinium dtpa; radiation-sensitizing agents; ht29 cells; anoxia; tumor hypoxia; nitroimidazoles; ef5; 2 (2 nitro 1h imidazol 1 yl) n (2,2,3,3,3 pentafluoropropyl)acetamide; etanidazole; hydrocarbons, fluorinated; atrasentan; ht29; tumor perfusion; perfusion; pyrrolidines
|